ストックスクリーナーアプリを入手
46.43
11.16%
-5.83
プレマーケット:
48.02
1.59
+3.42%
Tempus Ai Inc (TEM) 最新ニュース
Norges Bank Purchases New Position in Tempus AI, Inc. $TEM - MarketBeat
Contrarius Group Holdings Ltd Makes New Investment in Tempus AI, Inc. $TEM - MarketBeat
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - BioSpace
Tempus AI to present at Goldman Sachs healthcare conference - scanx.trade
A Quick Look at Today's Ratings for Tempus AI(TEM.US), With a Forecast Between $60 to $80 - Moomoo
Geode Capital Management LLC Boosts Holdings in Tempus AI, Inc. $TEM - MarketBeat
Tempus AI (NASDAQ:TEM) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Quanterix partners with Tempus AI on Alzheimer’s blood test - Investing.com
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India - INDmoney
Assessing Tempus AI (TEM) Valuation After Recent Share Price Rebound And Underpriced Growth Narrative - Yahoo Finance
TD Cowen raises Tempus AI stock price target on genomics strength - Investing.com
ARK's Stock Pick: $LLY & $TEM Hold Strong as AI Growth Stocks Plunge — Defensive Biotech Shines - Moomoo
TEM Technical Analysis & Stock Price Forecast - Intellectia AI
AI that predicts clinical outcomes? Tempus AI in focus after ASCO data reveal - MSN
Tempus (TEM) Gets Double-Digit Boost from New Partnerships - Insider Monkey
Tempus AI (NASDAQ:TEM) Trading Up 9.3%Time to Buy? - MarketBeat
Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month Lows - Benzinga
Tempus AI Stock Pops As FDA Win Fuels Growth Story - StocksToTrade
Why Tempus AI Stock Is Surging On Thursday?Tempus AI (NASDAQ:TEM) - Benzinga
Tempus AI falls on wider loss despite revenue beat By Investing.com - Investing.com Australia
Tempus AI (TEM) Jumps As FDA Win Fuels Bullish Momentum - timothysykes.com
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report? - Yahoo Finance
$Tempus AI (TEM.US)$ thanks for the ride [Drool] - Moomoo
TEM News | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
Tempus AI launches digital pathology open-source consortium - Investing.com UK
Tempus AI (TEM) director Epstein sells 250 shares in pre-planned trade - Stock Titan
Tempus AI Stock (TEM) Opinions on Analyst Coverage Initiation - Quiver Quantitative
Tempus AI launches digital pathology open-source consortium By Investing.com - Investing.com Nigeria
Tempus AI Launches Open-Source Digital Pathology Consortium With Yale New Haven Health - geneonline.com
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members - Yahoo Finance
Canaccord Genuity Sticks to Their Buy Rating for Tempus AI, Inc. Class A (TEM) - The Globe and Mail
$Tempus AI (TEM.US)$ someday… you will be wonderful again… - Moomoo
Tempus AI (NASDAQ:TEM) Now Covered by Analysts at Wolfe Research - MarketBeat
Canaccord reiterates Tempus AI stock rating citing growth potential By Investing.com - Investing.com South Africa
Canaccord reiterates Tempus AI stock rating citing growth potential - Investing.com
Tempus AI, Inc. $TEM Shares Bought by Lingotto Investment Management LLP - MarketBeat
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY) - The Globe and Mail
AXQ Capital LP Buys Shares of 26,002 Tempus AI, Inc. $TEM - MarketBeat
Tempus AI stock gains following the ALERT trial result announcement - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM) - The Globe and Mail
Wolfe Research initiates Tempus AI stock coverage with Peerperform By Investing.com - Investing.com South Africa
Wolfe Research initiates Tempus AI stock coverage with Peerperform - Investing.com UK
Tempus AI (TEM) Launches Next-Gen Sequencing Test for Oncology - GuruFocus
Stifel Maintains Tempus AI(TEM.US) With Hold Rating, Maintains Target Price $60 - Moomoo
Guggenheim Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Tempus xH test finds 40% more genomic findings than standard care - Stock Titan
Needham Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Tempus AI (NASDAQ:TEM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Tempus AI: Buy Rating Reiterated as Analyst Maintains $75 Price Target on Durable Growth and Improving Financial Profile - TipRanks
William Blair Maintains Tempus AI(TEM.US) With Hold Rating - Moomoo
Tempus AI Launches Next-Generation Agentic AI Platform for Oncology Drug Development - Moomoo
Tempus AI, Inc. (TEM) Stock Analysis: Exploring a 33.15% Potential Upside Amidst Healthcare Innovation - DirectorsTalk Interviews
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development - BioSpace
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology - BioSpace
Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades - Yahoo Finance
3.07%
7.34%
大文字化:
|
ボリューム (24 時間):